ClearPoint Neuro (CLPT) awards 147,275 restricted stock units to CEO Burnett

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. reported that CEO and President Joseph Burnett acquired a grant of 147,275 restricted stock units. Each unit represents a contingent right to receive one share of CLPT common stock.

The restricted stock units vest over three years: 20% of the total shares on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning the award with multi-year executive retention and performance incentives.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BURNETT JOSEPH

Role CEO and President

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	147,275	$0.00	--

Holdings After Transaction: Restricted Stock Units — 147,275 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029.

Form 4 Insider Transactions: What Each Field Means →

02/19/2026 - 04:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURNETT JOSEPH

(Last)

(First)

(Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH

92075

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	02/17/2026		A		147,275		⁽²⁾	⁽²⁾	Common Stock	147,275	$0	147,275	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.

2. The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029.

	/s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for Joseph Burnett?

ClearPoint Neuro reported that CEO and President Joseph Burnett received a grant of 147,275 restricted stock units. These units are a form of equity compensation that may convert into CLPT common shares if the vesting conditions and time-based schedule are satisfied.

How many restricted stock units were granted to the CLPT CEO?

Joseph Burnett was granted 147,275 restricted stock units. This entire amount reflects a single equity award, structured to vest in stages over three years, subject to the stated vesting dates and continued service or other applicable conditions described in the grant terms.

What does each restricted stock unit represent for ClearPoint Neuro (CLPT)?

Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro common stock. The units themselves are not shares until they vest and settle, at which point they can convert into CLPT shares if all requirements are met.

What is the vesting schedule for Joseph Burnett’s CLPT restricted stock units?

The restricted stock units vest in three tranches: 20% of the total shares on February 17, 2027, 40% on February 17, 2028, and 40% on February 17, 2029. This creates a long-term incentive horizon for the CEO’s equity compensation.

Did Joseph Burnett buy CLPT shares on the open market in this Form 4?

No, this Form 4 reflects a grant or award acquisition of restricted stock units, coded as an “A” transaction. The units were awarded at a stated price of $0.00 per unit, consistent with stock-based compensation rather than an open-market purchase of existing CLPT shares.

How many derivative securities does Joseph Burnett hold after this CLPT award?

After this transaction, Joseph Burnett beneficially holds 147,275 derivative securities in the form of restricted stock units. These units are subject to the specified vesting schedule before they can convert into shares of ClearPoint Neuro common stock, assuming applicable conditions are fulfilled.